JP6440259B2 - Ｈｂｖ感染及び関連疾患を処置するためのポリペプチド及び抗体 - Google Patents

Ｈｂｖ感染及び関連疾患を処置するためのポリペプチド及び抗体 Download PDF

Info

Publication number
JP6440259B2
JP6440259B2 JP2015516418A JP2015516418A JP6440259B2 JP 6440259 B2 JP6440259 B2 JP 6440259B2 JP 2015516418 A JP2015516418 A JP 2015516418A JP 2015516418 A JP2015516418 A JP 2015516418A JP 6440259 B2 JP6440259 B2 JP 6440259B2
Authority
JP
Japan
Prior art keywords
protein
hbsag
hbv
antibody
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015516418A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015522563A (ja
Inventor
ユアン、クアン
チャン、ティエンイン
ルオ、ウェンシン
チェン、イーシン
チャン、ジュン
シャ、ニンシャオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yang Sheng Tang Co Ltd
Original Assignee
Yang Sheng Tang Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yang Sheng Tang Co Ltd filed Critical Yang Sheng Tang Co Ltd
Publication of JP2015522563A publication Critical patent/JP2015522563A/ja
Application granted granted Critical
Publication of JP6440259B2 publication Critical patent/JP6440259B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • G01N33/5764—Hepatitis B surface antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/02—Hepadnaviridae, e.g. hepatitis B virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
JP2015516418A 2012-06-11 2013-06-06 Ｈｂｖ感染及び関連疾患を処置するためのポリペプチド及び抗体 Active JP6440259B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201210190329 2012-06-11
CN201210190329.X 2012-06-11
PCT/CN2013/076832 WO2013185558A1 (zh) 2012-06-11 2013-06-06 用于治疗hbv感染及相关疾病的多肽及抗体

Publications (2)

Publication Number Publication Date
JP2015522563A JP2015522563A (ja) 2015-08-06
JP6440259B2 true JP6440259B2 (ja) 2018-12-19

Family

ID=49757513

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015516418A Active JP6440259B2 (ja) 2012-06-11 2013-06-06 Ｈｂｖ感染及び関連疾患を処置するためのポリペプチド及び抗体

Country Status (11)

Country Link
US (2) US9751914B2 (Direct)
EP (2) EP2860188B1 (Direct)
JP (1) JP6440259B2 (Direct)
KR (2) KR102106782B1 (Direct)
CN (2) CN103483421B (Direct)
AU (1) AU2013276015B2 (Direct)
BR (2) BR122020023349B1 (Direct)
CA (2) CA2943258C (Direct)
ES (2) ES2834072T3 (Direct)
IN (1) IN2014DN10288A (Direct)
WO (1) WO2013185558A1 (Direct)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103483421B (zh) * 2012-06-11 2019-10-22 厦门大学 用于治疗hbv感染及相关疾病的多肽及抗体
WO2016085284A1 (ko) * 2014-11-28 2016-06-02 (주)셀트리온 B형 간염 바이러스 표면 항원의 에피토프 및 이에 특이적으로 결합하는 b형 간염 바이러스 중화 결합 분자
BR112018007121A2 (pt) * 2015-10-09 2018-11-06 Xiamen University anticorpo ou antígeno de ligação ao fragmento do mesmo, anticorpo humanizado ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucléico isolada, vetor, célula hospedeira, método para preparar o anticorpo ou um antígeno de ligação ao fragmento do mesmo, composição farmacêutica, uso do anticorpo ou um antígeno de ligação ao fragmento do mesmo e método para prevenir ou tratar infecção hbv ou uma doença associada com a infecção hbv
WO2018064602A1 (en) * 2016-09-30 2018-04-05 Baylor College Of Medicine Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease
US10987418B2 (en) 2017-02-17 2021-04-27 Xiamen University Polypeptide carrier for presenting target polypeptide and uses thereof
RU2765878C2 (ru) * 2017-04-07 2022-02-04 Сямэнь Юниверсити Антитела для лечения инфекции гепатитом в и связанных с ней заболеваний
CN109718364A (zh) * 2017-10-27 2019-05-07 上海贺普药业股份有限公司 充分剂量条件下治疗乙肝病毒相关肝病的药物和方法
JP7490574B2 (ja) * 2018-05-31 2024-05-27 ノバルティス アーゲー Ｂ型肝炎抗体
KR102084912B1 (ko) * 2019-01-17 2020-03-05 주식회사 녹십자 B형 간염 바이러스 표면 항원의 입체 에피토프 및 이에 특이적으로 결합하는 항체
GB201904328D0 (en) * 2019-03-28 2019-05-15 Immunocore Ltd Specific binding molecules
US20220251173A1 (en) * 2019-05-23 2022-08-11 Xiamen University Anti-hepatitis b virus antibodies and use thereof
KR20220074917A (ko) 2019-09-30 2022-06-03 길리애드 사이언시즈, 인코포레이티드 Hbv 백신 및 hbv를 치료하는 방법
CN111187349A (zh) * 2019-10-30 2020-05-22 四川迈克生物新材料技术有限公司 单克隆抗体的制备方法
CN113138276B (zh) * 2020-01-19 2022-09-16 厦门万泰凯瑞生物技术有限公司 用于检测HBcAg的方法及抗体
CN113717283B (zh) * 2020-05-25 2023-05-26 厦门万泰凯瑞生物技术有限公司 一种抗乙型肝炎病毒e抗原的单克隆抗体及其应用
CN111879932B (zh) * 2020-06-24 2022-09-27 南方医科大学南方医院 乙型肝炎病毒(hbv)特异性b细胞表位检测方法及其应用
CN115246881B (zh) * 2021-02-02 2025-04-11 浙江理工大学 一种抗HBsAg鲨鱼单域抗体或其抗原结合片段及其应用
CN113234143B (zh) * 2021-05-10 2021-12-14 合肥金域医学检验实验室有限公司 一种快速检测病毒的核酸抗体试剂盒
CN114671947B (zh) * 2022-02-28 2024-04-09 中国科学院生物物理研究所 乙肝病毒不同亚型表面s蛋白高亲和力纳米抗体及其应用
CN116162153B (zh) * 2022-09-01 2024-09-10 复旦大学附属中山医院 一种乙肝病毒表面抗原的单克隆抗体及其应用
CN116751262B (zh) * 2023-07-31 2024-09-06 重庆医科大学国际体外诊断研究院 靶向乙型肝炎病毒核心蛋白的多肽及其应用
CN119161462B (zh) * 2024-10-09 2025-08-19 深圳市第三人民医院(深圳市肝病研究所) 一株乙型肝炎病毒核心蛋白的单克隆抗体cAbD4及其制备与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4599231A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
WO1985004103A1 (en) * 1984-03-09 1985-09-26 Scripps Clinic And Research Foundation Synthetic hepatitis b virus vaccine including both t cell anc b cell determinants
US20110097352A9 (en) 1992-01-29 2011-04-28 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
JP2000514643A (ja) * 1996-04-18 2000-11-07 アボツト・ラボラトリーズ Ｂ型肝炎表面抗原のａ―決定基の抗原エピトープ及びその利用法
DE60027581T2 (de) * 1999-10-08 2007-05-10 Celltech Pharma Europe Ltd., Slough Design von immunogene
ES2307832T3 (es) 2001-12-03 2008-12-01 Amgen Fremont Inc. Clasificacion de anticuerpos basada en las caracteristicas de union.
US7144712B2 (en) * 2003-07-30 2006-12-05 Vaccine Research Institute Of San Diego Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof
JP4948783B2 (ja) * 2005-05-18 2012-06-06 シスメックス株式会社 抗ＨＢｓモノクローナル抗体
CN101606066A (zh) * 2006-10-30 2009-12-16 株式会社先端生命科学研究所 乙型肝炎病毒表面抗原的分析方法
CN101748129A (zh) * 2008-12-04 2010-06-23 上海裕隆临床检验中心有限公司 人源乙肝病毒表面抗体的制备方法
CN103483421B (zh) * 2012-06-11 2019-10-22 厦门大学 用于治疗hbv感染及相关疾病的多肽及抗体

Also Published As

Publication number Publication date
CN106046155B (zh) 2019-11-22
CA2943258C (en) 2020-12-22
KR20150043289A (ko) 2015-04-22
HK1203978A1 (en) 2015-11-06
US9751914B2 (en) 2017-09-05
EP3308798A3 (en) 2018-05-30
CN103483421A (zh) 2014-01-01
JP2015522563A (ja) 2015-08-06
CN103483421B (zh) 2019-10-22
WO2013185558A1 (zh) 2013-12-19
EP3308798B1 (en) 2020-09-09
BR112014030797A2 (pt) 2017-07-25
EP2860188A4 (en) 2016-04-27
AU2013276015B2 (en) 2017-04-20
EP2860188B1 (en) 2020-10-21
KR20190011247A (ko) 2019-02-01
CA2876020A1 (en) 2013-12-19
US20180002382A1 (en) 2018-01-04
AU2013276015A1 (en) 2014-12-18
KR102106782B1 (ko) 2020-05-07
CA2876020C (en) 2018-08-21
IN2014DN10288A (Direct) 2015-08-07
ES2834072T3 (es) 2021-06-16
ES2843675T3 (es) 2021-07-20
KR101944263B1 (ko) 2019-02-01
EP3308798A2 (en) 2018-04-18
CA2943258A1 (en) 2013-12-19
US10246494B2 (en) 2019-04-02
EP2860188A1 (en) 2015-04-15
CN106046155A (zh) 2016-10-26
US20150246948A1 (en) 2015-09-03
BR122020023349B1 (pt) 2023-02-07

Similar Documents

Publication Publication Date Title
JP6440259B2 (ja) Ｈｂｖ感染及び関連疾患を処置するためのポリペプチド及び抗体
CN105669838B (zh) 来自水痘-带状疱疹病毒gE蛋白的中和表位及针对其的抗体
JP6462599B2 (ja) Ｒｓｖ融合タンパク質のエピトープ及びそのエピトープを認識する抗体
JP6722233B2 (ja) 抗ｈｓｖ抗体
JP2020036612A (ja) Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン
KR20180012245A (ko) 다가 b형 간염 바이러스 항원 결합 분자 및 그의 용도
CN103483447A (zh) 抗hpv l1 蛋白的广谱单克隆抗体或其抗原结合片段及它们的用途
JP6949012B2 (ja) Ｂ型肝炎表面抗原に対する抗体及びその使用
RU2585525C2 (ru) Эпитоп поверхностного антигена вируса гепатита b и его применение
CN113717283A (zh) 一种抗乙型肝炎病毒e抗原的单克隆抗体及其应用
CN114729371B (zh) 能够抑制乙型肝炎病毒(hbv)对人肝细胞的感染的与人ntcp结合的抗体
HK1203978B (en) Polypeptides and antibodies for treating hbv infection and related diseases
US20080075717A1 (en) Antigen Imitating Extracellular Areas of Membrane Proteins of Type III Produced from Intracellular Pathogenic Micro-Organisms, Derived Conformational Antibodies and the Use Thereof
JP2022537544A (ja) Ｊｃウイルスに対するモノクローナル抗体
WO2014065822A1 (en) Hepatitis c virus neutralizing epitopes, antibodies, and methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180830

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181026

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20181102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181102

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181116

R150 Certificate of patent or registration of utility model

Ref document number: 6440259

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250